EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Strategies to Improve Cannabidiol Bioavailability and Drug Delivery

Saoirse Elizabeth O'Sullivan iD, Sanne Skov Jensen, Aditya Reddy Kolli iD, Gitte Nykjær Nikolajsen, Heidi Ziegler Bruun, Julia Hoeng

Pharmaceuticals · 13.02.2024 · 17 (2) · 244

DOI: 10.3390/ph17020244 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 13.02.2024. Verfasst von Saoirse Elizabeth O'Sullivan und 5 weiteren Autor:innen. Beteiligte Einrichtung: CanPharmaConsulting, Nottingham NG9 3BB, UK. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fertin Pharma and Vectura Fertin Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The poor physicochemical properties of cannabidiol (CBD) hamper its clinical development. The aim of this review was to examine the literature to identify novel oral products and delivery strategies for CBD, while assessing their clinical implications and translatability. Evaluation of the published literature revealed that oral CBD strategies are primarily focused on lipid-based and emulsion solutions or encapsulations, which improve the overall pharmacokinetics (PK) of CBD. Some emulsion formulations demonstrate more rapid systemic delivery. Variability in the PK effects of different oral CBD products is apparent across species. Several novel administration routes exist for CBD delivery that may offer promise for specific indications. For example, intranasal administration and inhalation allow quick delivery of CBD to the plasma and the brain, whereas transdermal and transmucosal administration routes deliver CBD systemically more slowly. There are limited but promising data on novel delivery routes such as intramuscular and subcutaneous. Very limited data show that CBD is generally well distributed across tissues and that some CBD products enable increased delivery of CBD to different brain regions. However, evidence is limited regarding whether changes in CBD PK profiles and tissue distribution equate to superior therapeutic efficacy across indications and whether specific CBD products might be suited to particular indications.

Schlagwörter

Stichwörter der Autor:innen

cannabidiolclinicaldiseasepharmacodynamicspharmacokineticsroute of administrationtissue distribution

Autor:innen und Institutionen

  • CanPharmaConsulting, Nottingham NG9 3BB, UK.
  • Fertin Pharma, Dandyvej 19, 7100 Vejle, Denmark.
  • PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, 2000 Neuchâtel, Switzerland.
  • Vectura Fertin Pharma, 4058 Basel, Switzerland.

ORCID-Profile: Saoirse Elizabeth O'Sullivan, Aditya Reddy Kolli

Förderung

  • Fertin Pharma and Vectura Fertin Pharma

Zitieren

APA

O'Sullivan, S. E., Jensen, S. S., Kolli, A. R., Nikolajsen, G. N., Bruun, H. Z., & Hoeng, J. (2024). Strategies to Improve Cannabidiol Bioavailability and Drug Delivery. Pharmaceuticals, 17(2), 244. https://doi.org/10.3390/ph17020244

Vancouver

O'Sullivan SE, Jensen SS, Kolli AR, Nikolajsen GN, Bruun HZ, Hoeng J. Strategies to Improve Cannabidiol Bioavailability and Drug Delivery. Pharmaceuticals. 2024;17(2):244. doi:10.3390/ph17020244

BibTeX
@article{OSullivan2024,
  author = {O'Sullivan, Saoirse Elizabeth and Jensen, Sanne Skov and Kolli, Aditya Reddy and Nikolajsen, Gitte Nykjær and Bruun, Heidi Ziegler and Hoeng, Julia},
  title = {Strategies to Improve Cannabidiol Bioavailability and Drug Delivery},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {2},
  pages = {244},
  doi = {10.3390/ph17020244}
}
Kostenlos starten →